Johnson & Johnson Reports New Data on ICOTYDE Skin Clearance Rates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy JNJ?
Source: Newsfilter
- Clinical Trial Results: Johnson & Johnson presented at the 2026 American Academy of Dermatology Annual Meeting that ICOTYDE's complete skin clearance rates increased from 41% to 49% and from 33% to 48% at Week 52 in the ICONIC-ADVANCE 1 and 2 studies, indicating significant efficacy in treating moderate-to-severe plaque psoriasis.
- Adolescent Patient Performance: In the ICONIC-LEAD study, nearly 60% of adolescents achieved complete skin clearance at Week 52, specifically 57% PASI 100 and 61% IGA 0, demonstrating ICOTYDE's favorable safety and efficacy profile in the adolescent population.
- Safety Analysis: The adverse event profile of ICOTYDE through Week 52 was consistent with that observed at Weeks 16 and 24, with no new safety signals identified, indicating that the drug's long-term safety has been validated, potentially offering patients a more reliable treatment option.
- Market Outlook: The successful clinical data for ICOTYDE not only provides new treatment options for patients but may also enhance Johnson & Johnson's competitiveness in the psoriasis market, addressing the growing patient demand and further solidifying its leadership position in the biopharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 239.240
Low
190.00
Averages
218.50
High
240.00
Current: 239.240
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson & Johnson Reports ICOTYDE Skin Clearance Data
- Clinical Trial Results: Johnson & Johnson presented data at the 2026 American Academy of Dermatology Annual Meeting showing that ICOTYDE's complete skin clearance rates increased from 41% to 49% and from 33% to 48% in the ICONIC-ADVANCE 1 and 2 studies from Week 24 to Week 52, demonstrating significant efficacy in treating moderate-to-severe plaque psoriasis.
- Adolescent Patient Outcomes: In the ICONIC-LEAD study, nearly 60% of adolescents achieved complete skin clearance (57% PASI 100, 61% IGA 0) at Week 52, indicating ICOTYDE's effectiveness and safety in this age group, potentially providing a new treatment option for young patients.
- Safety Profile Analysis: Throughout the 52-week treatment period, no new safety signals were identified for ICOTYDE, and its adverse event and infection rates were lower than those of the comparator drug deucravacitinib, reinforcing patient confidence in its safety.
- Market Potential: As the first targeted oral peptide, ICOTYDE offers a unique treatment option that could transform the treatment landscape for moderate-to-severe plaque psoriasis, addressing the need for long-term effective therapies and presenting significant market opportunities.
See More
Impact of Iran War on Global Economies
- Market Focus: Investors are closely monitoring the potential impact of the Iran war on the U.S. and global economies as they head into the Easter week, reflecting market sensitivity to geopolitical risks.
- Economic Outlook Volatility: Analysts warn that escalating conflict could lead to rising energy prices, which may affect inflation and consumer spending, thereby negatively impacting economic growth.
- Investment Strategy Adjustments: Investors may reassess their portfolios, considering allocations to safe-haven assets to mitigate potential market volatility and uncertainty, indicating a cautious market sentiment.
- Global Market Interconnection: The ongoing Iran war could trigger a ripple effect across global markets, particularly in countries heavily reliant on energy, prompting investors to stay alert to developments in related sectors.
See More
Johnson & Johnson Reports New Data on ICOTYDE Skin Clearance Rates
- Clinical Trial Results: Johnson & Johnson presented at the 2026 American Academy of Dermatology Annual Meeting that ICOTYDE's complete skin clearance rates increased from 41% to 49% and from 33% to 48% at Week 52 in the ICONIC-ADVANCE 1 and 2 studies, indicating significant efficacy in treating moderate-to-severe plaque psoriasis.
- Adolescent Patient Performance: In the ICONIC-LEAD study, nearly 60% of adolescents achieved complete skin clearance at Week 52, specifically 57% PASI 100 and 61% IGA 0, demonstrating ICOTYDE's favorable safety and efficacy profile in the adolescent population.
- Safety Analysis: The adverse event profile of ICOTYDE through Week 52 was consistent with that observed at Weeks 16 and 24, with no new safety signals identified, indicating that the drug's long-term safety has been validated, potentially offering patients a more reliable treatment option.
- Market Outlook: The successful clinical data for ICOTYDE not only provides new treatment options for patients but may also enhance Johnson & Johnson's competitiveness in the psoriasis market, addressing the growing patient demand and further solidifying its leadership position in the biopharmaceutical sector.
See More
Eli Lilly Faces Competitive Pressure but Maintains Optimistic Outlook
- Market Performance: Despite leading the weight-loss medicine market, Eli Lilly's shares have fallen 15% this year, raising concerns about intensified competition in its core niche that could erode pricing power and profits.
- Margin Improvement: Since 2020, Eli Lilly's gross and operating margins have significantly improved, with Q4 2025 margins surpassing those of peers, indicating that sales are growing much faster than expenses, reflecting enhanced manufacturing efficiency.
- Manufacturing Capacity Investment: Eli Lilly has invested $55 billion since 2020 to expand its manufacturing capacity, which may hurt profits and margins in the short term but is expected to lower costs and boost capacity, driving significant economies of scale in the long run.
- Artificial Intelligence Initiatives: Eli Lilly has built the largest supercomputer in the pharmaceutical industry with Nvidia's help, aiming to accelerate drug discovery and clinical trial design, with even a 5% reduction in time and costs potentially having a positive impact across the business.
See More
Eli Lilly's Competitive Margin Analysis
- Margin Improvement: Since 2020, Eli Lilly has significantly improved its gross and operating margins, with Q4 2025 margins surpassing those of peers, indicating that sales are growing much faster than expenses, reflecting enhanced drug manufacturing efficiency.
- Competitive Market Pressure: Despite leading the weight-loss drug market, Eli Lilly's shares have fallen 15% this year, raising concerns about potential fierce competition that could erode pricing power and profits in the future.
- Manufacturing Capacity Investment: Eli Lilly has invested $55 billion in expanding its manufacturing capacity since 2020, which may hurt profits in the short term but is expected to lower costs and enhance economies of scale in the long run.
- Artificial Intelligence Applications: Eli Lilly has partnered with Nvidia to build the largest supercomputer in the pharmaceutical industry, aiming to accelerate drug discovery and clinical trial design, with even a 5% reduction in time and costs potentially benefiting the entire business.
See More
Intuitive Surgical Faces Challenges and Opportunities Ahead
- Strong Financial Performance: In Q4, Intuitive Surgical's revenue rose 19% year-over-year to $2.87 billion, while adjusted earnings per share increased 14.5% to $2.53, indicating the company's sustained growth potential in the medical device sector despite tariff pressures.
- Increased Market Competition: With competitors like Medtronic and Johnson & Johnson entering the robotic-assisted surgery market, Intuitive Surgical's market share may be threatened, particularly as its valuation stands at 47.6 times earnings, raising investor concerns about future performance.
- Long-Term Growth Potential: Despite short-term challenges, the robotic-assisted surgery market presents expansion opportunities for Intuitive Surgical over the next decade, especially as its da Vinci system has established a strong competitive moat through extensive usage data and proven surgical outcomes.
- Enhanced Pricing Power: The projected 1.2% negative impact of tariffs on net revenue could be offset by modest price increases, as Intuitive Surgical's market-leading technology and demonstrated patient outcomes provide it with pricing power, suggesting potential improvements in profitability going forward.
See More
Johnson & Johnson Reports ICOTYDE Skin Clearance Data
- Clinical Trial Results: Johnson & Johnson presented data at the 2026 American Academy of Dermatology Annual Meeting showing that ICOTYDE's complete skin clearance rates increased from 41% to 49% and from 33% to 48% in the ICONIC-ADVANCE 1 and 2 studies from Week 24 to Week 52, demonstrating significant efficacy in treating moderate-to-severe plaque psoriasis.
- Adolescent Patient Outcomes: In the ICONIC-LEAD study, nearly 60% of adolescents achieved complete skin clearance (57% PASI 100, 61% IGA 0) at Week 52, indicating ICOTYDE's effectiveness and safety in this age group, potentially providing a new treatment option for young patients.
- Safety Profile Analysis: Throughout the 52-week treatment period, no new safety signals were identified for ICOTYDE, and its adverse event and infection rates were lower than those of the comparator drug deucravacitinib, reinforcing patient confidence in its safety.
- Market Potential: As the first targeted oral peptide, ICOTYDE offers a unique treatment option that could transform the treatment landscape for moderate-to-severe plaque psoriasis, addressing the need for long-term effective therapies and presenting significant market opportunities.
See More
Impact of Iran War on Global Economies
- Market Focus: Investors are closely monitoring the potential impact of the Iran war on the U.S. and global economies as they head into the Easter week, reflecting market sensitivity to geopolitical risks.
- Economic Outlook Volatility: Analysts warn that escalating conflict could lead to rising energy prices, which may affect inflation and consumer spending, thereby negatively impacting economic growth.
- Investment Strategy Adjustments: Investors may reassess their portfolios, considering allocations to safe-haven assets to mitigate potential market volatility and uncertainty, indicating a cautious market sentiment.
- Global Market Interconnection: The ongoing Iran war could trigger a ripple effect across global markets, particularly in countries heavily reliant on energy, prompting investors to stay alert to developments in related sectors.
See More
Johnson & Johnson Reports New Data on ICOTYDE Skin Clearance Rates
- Clinical Trial Results: Johnson & Johnson presented at the 2026 American Academy of Dermatology Annual Meeting that ICOTYDE's complete skin clearance rates increased from 41% to 49% and from 33% to 48% at Week 52 in the ICONIC-ADVANCE 1 and 2 studies, indicating significant efficacy in treating moderate-to-severe plaque psoriasis.
- Adolescent Patient Performance: In the ICONIC-LEAD study, nearly 60% of adolescents achieved complete skin clearance at Week 52, specifically 57% PASI 100 and 61% IGA 0, demonstrating ICOTYDE's favorable safety and efficacy profile in the adolescent population.
- Safety Analysis: The adverse event profile of ICOTYDE through Week 52 was consistent with that observed at Weeks 16 and 24, with no new safety signals identified, indicating that the drug's long-term safety has been validated, potentially offering patients a more reliable treatment option.
- Market Outlook: The successful clinical data for ICOTYDE not only provides new treatment options for patients but may also enhance Johnson & Johnson's competitiveness in the psoriasis market, addressing the growing patient demand and further solidifying its leadership position in the biopharmaceutical sector.
See More
Eli Lilly Faces Competitive Pressure but Maintains Optimistic Outlook
- Market Performance: Despite leading the weight-loss medicine market, Eli Lilly's shares have fallen 15% this year, raising concerns about intensified competition in its core niche that could erode pricing power and profits.
- Margin Improvement: Since 2020, Eli Lilly's gross and operating margins have significantly improved, with Q4 2025 margins surpassing those of peers, indicating that sales are growing much faster than expenses, reflecting enhanced manufacturing efficiency.
- Manufacturing Capacity Investment: Eli Lilly has invested $55 billion since 2020 to expand its manufacturing capacity, which may hurt profits and margins in the short term but is expected to lower costs and boost capacity, driving significant economies of scale in the long run.
- Artificial Intelligence Initiatives: Eli Lilly has built the largest supercomputer in the pharmaceutical industry with Nvidia's help, aiming to accelerate drug discovery and clinical trial design, with even a 5% reduction in time and costs potentially having a positive impact across the business.
See More
Eli Lilly's Competitive Margin Analysis
- Margin Improvement: Since 2020, Eli Lilly has significantly improved its gross and operating margins, with Q4 2025 margins surpassing those of peers, indicating that sales are growing much faster than expenses, reflecting enhanced drug manufacturing efficiency.
- Competitive Market Pressure: Despite leading the weight-loss drug market, Eli Lilly's shares have fallen 15% this year, raising concerns about potential fierce competition that could erode pricing power and profits in the future.
- Manufacturing Capacity Investment: Eli Lilly has invested $55 billion in expanding its manufacturing capacity since 2020, which may hurt profits in the short term but is expected to lower costs and enhance economies of scale in the long run.
- Artificial Intelligence Applications: Eli Lilly has partnered with Nvidia to build the largest supercomputer in the pharmaceutical industry, aiming to accelerate drug discovery and clinical trial design, with even a 5% reduction in time and costs potentially benefiting the entire business.
See More
Intuitive Surgical Faces Challenges and Opportunities Ahead
- Strong Financial Performance: In Q4, Intuitive Surgical's revenue rose 19% year-over-year to $2.87 billion, while adjusted earnings per share increased 14.5% to $2.53, indicating the company's sustained growth potential in the medical device sector despite tariff pressures.
- Increased Market Competition: With competitors like Medtronic and Johnson & Johnson entering the robotic-assisted surgery market, Intuitive Surgical's market share may be threatened, particularly as its valuation stands at 47.6 times earnings, raising investor concerns about future performance.
- Long-Term Growth Potential: Despite short-term challenges, the robotic-assisted surgery market presents expansion opportunities for Intuitive Surgical over the next decade, especially as its da Vinci system has established a strong competitive moat through extensive usage data and proven surgical outcomes.
- Enhanced Pricing Power: The projected 1.2% negative impact of tariffs on net revenue could be offset by modest price increases, as Intuitive Surgical's market-leading technology and demonstrated patient outcomes provide it with pricing power, suggesting potential improvements in profitability going forward.
See More
